Omagine, OMAG, Profile

 

Omagine, Inc. (OTCQB: OMAG) Profile, Summary

 

Omagine is an entertainment, hospitality and tourism company with significant residential and commercial real estate development and property management activities.

 

The company is headquartered in New York City and has a subsidiary in Muscat, Oman. Omagine is focused on MENA Region real-estate development and hospitality opportunities because the company believes the enormous financial resources in the MENA region combined with a recent shift in economic development strategies of regional Governments present huge opportunities. (See how OMAG could benefit from it, click here)

 

The Vision

The company has signed a $2.5 billion development agreement with the Government of Oman, developing a mixed-use Tourism/Residential and Commercial/Retail project known as - The Omagine Project. The 245 acre prime beachfront property is located just 6 miles from Muscat International Airport. The beautiful Pearl shaped buildings will overlook the serene Gulf of Oman, surrounded by a vibrant art and culture scene, poised to inspire the world.

 

The Omagine Project is designed as an exquisite, modern architectural marvel built with environmentally friendly materials in a family friendly living/working space. It blends local values and customs for today's global citizens where residents and visitors live, work and play in complete harmony with nature.

 

The existing majestic Sultan Qaboos Street, home to Muscat's many landmarks, provides easy access to The Omagine Project, where art and culture thrive, residents and visitors experience Arabian hospitality, dine in fine restaurants and shop at exclusive showrooms of global brands. (See project overview, click here)

 

The Future

Most Americans are familiar with The Palm Islands of Dubai. The Palm started with a vision and a simple rendering, despite huge challenges, the vision came true. Dubai became one of the world’s top tourist destinations and one of most expensive real estate markets in the world.

THE PALM

 

THE PALM

 

The Omagine Project – and its Pearls – has the potential to become the next major tourism destination and one of the most highly desired real estate markets. Muscat could become the next hot destination for the tourists around the world.

 

The Omagine Project – The Pearls

The Omagine Project – The Pearls

 

 

Timing and Location is Everything!

The timing couldn't be better for Chinese investors. The Stock Market in China down sharply and the Chinese economy slowing down considerably. Chinese investors looking for an alternative, discovered Dubai. Investors from China are flocking to Dubai. Huge demand from investors is driving up real estate prices in Dubai and the cost of living and doing business in Dubai has increased dramatically.

 

We believe, The Omagine Project (Muscat) offers the next great opportunity for investors and Global corporations doing business in the Middle East. Muscat's low cost of living and cheaper office space offers a better ROI.

 

The Pearls (Muscat) expected to meet or exceed the lifestyle choice and luxury for less. It’s a great opportunity for Global corporations to establish their MENA headquarters in Muscat. Also, a unique opportunity for accredited investors seeking to diversify their portfolios.

 

Source: The Company, OxBridge Research, Daily Stock Deal, OTC King, OTC Stock Wire

 

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. If you want to learn more or get your company featured on Daily Stock Deal, please contact the Editor. editor [@] DailyStockDeals.com

 

XLI Technologies, XLIT, Profile

 

 

XLI Technologies, XLIT, Profile, Summary

 

XLI Technologies, Inc. is a technology and multimedia distribution company, featuring just one of their products and services: Printed LightSheets. XLI Technologies, Inc., provides innovative lighting solutions within the multimedia, theatrical distribution, and entertainment sectors. Our unique Printed LightSheets technology enables us to provide an exceptional value proposition for our clients as well as their customers, by delivering cutting-edge positioning techniques as well as movie production tools. In addition to leading the way in technology, our business model enables our clients to maximize their profitability in the interest of fostering mutually beneficial financial opportunities.

 

 

NANOTECHNOLOGY

Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. XLI Technology brings Printed LightSheets’ Nanotechnology to market: a revolutionary, patented light source that gives off vibrant colors and provides a highly efficient, 100% environmentally friendly light-source alternative.

 

 

AUTOMOTIVE INDUSTRY

XLI Technologies puts advertising and promotion on the move with its Printed LightSheets offerings for the automotive industry. Options run the gamut in exterior lighting surfaces, with car hood wraps, quarter-panel lighting and windows that make an indelible impression. In the interior, eye-catching capabilities include illuminated headliners, seats, floormats, displays and interior door panels.

 

 

LIGHT UP MOVIE THEATER ADS AND PROMOTIONS

When it comes to advertising and promotions, drawing attention and increasing focus are absolutely paramount. In addition to improving the visual impact of traditional poster presentations in the theater environment, Printed LightSheets offers new and creative advertising space in areas where advertising was unable to effectively be used before, such as “canvertizing” (advertising on a trashcan). Each additional square foot of light advertising creates an environment of excitement and additional advertising revenue opportunities.

 

 

PRODUCTION LIGHTING

XLI Technologies’ motion picture division is focused exclusively on products for movie studios, production and distribution companies, advertising, and talent and management agencies. This program offers volume discounts with fast delivery (same day, overnight, 5-day and/or 10-day delivery). Every Printed LightSheet comes with a transformer that powers the Printed LightSheet. Portable Backlit Packages are available for all 5 sizes—so light, portable and convenient that they can be considered a carry on when flying and traveling. (All Printed LightSheets also come with a warranty.) The current standard configurations include:

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

 

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured on our network, please don't hesitate to contact the Editor. editor [@] DailyStockDeals.com

 

 

Gala Global, GLAG, Profile

 

Gala Global, GLAG, Profile

GALA Global, Inc. is a publicly traded development stage company which plans to expand in the Hemp and Cannabis industries. The Company is refocusing its purpose on the development, research, and commercialization of products derived from Hemp and Cannabis Plant, while expanding the clothing operations and upcoming Hemp based fiber apparel and accessories division.

 

The Hemp Industries Association (HIA) estimated that the 2014 retail sales value of hemp food, body/beauty care, clothing and various other hemp products sold in the United States were more than $620 million.


Industrial Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including pasta, tortilla chips, salad dressings, snack products and frozen desserts. Hemp seed contains a complete protein and the seed oil is the richest source of essential fatty acids (Omega-6 and Omega-3) with the perfect ratio of 3:1. Hemp seed oil is also used in nutraceuticals and health care products.

Hemp is undergoing rapid growth as a natural fiber source in everything from clothing and textiles to automotive composites. Although it is legal to import and sale industrial hemp products in the U.S., it is not yet legal to commercially grow industrial hemp in the U.S. The 2013 farm bill was signed into law in February 2014 and contained a hemp amendment, Sec. 7606 Legitimacy of Industrial Hemp Research, which allows states that have already legalized the crop to cultivate hemp within the parameters of state agriculture departments and research institutions.

The Industrial Hemp Farming Act was introduced (in January 2015) in both the House and Senate, H.R. 525 and S. 134 respectively. If passed, the bill would remove all federal restrictions on the cultivation of industrial hemp, and remove its classification as a Schedule 1 controlled substance.

 

Subsidiaries

Gala Global owns and operates several subsidiaries including, Cannabis Ventures Inc., Cannabis Ventures (Canada) and CBDLiving.

 

Cannabis Ventures, Inc.

Cannabis Ventures (CVI) was organized for the purpose of developing leading scientific processing to cultivate a bio-medical grade Cannabis plant featuring a higher concentration Cannabidiol (CBD) value with natural healing powers. The team along with expert consultants which have specific expertise in pharmaceutical sciences (medicinal chemistry of natural products) and herbal pharmacology. Cannabis Ventures plans to supply the medical marijuana market along with alternate medicinal supply for global market for highly enriched plant concentration of CannabidiolFor more information visit www.cannabisventuresinc.com

 

Cannabis Ventures (USA)

Cannabis Venture signed a management agreement with America's first approved dispensary, Compassionate Caregiver! Compassionate Caregiver based in California became the first dispensary to provide Medical Marijuana in the United States.

 

Cannabis Ventures (Canada)

The company's Canadian subsidiary filed application to be a Licensed Producer under the Medical Marijuana for Medical Purposes Regulations (MMPR) with Health Canada. Cannabis Ventures is currently in the process in establishing operations in British Columbia to service the Medical Marijuana market.

Cannabis Ventures (Canada) recently signed a turn key management contract with a company based in Ontario, Canada. Cannabis Venture will assist in designing, equipment procurement, installation and help the company obtain license from Health Canada.

 

CBDLivin

Gala Global created this special division to take advantage of $18 Billion dollar supplement industry. The company plans to introduce CBD infused dietary supplements and sports nutrition products in 23 states and the District of Columbia in the near future. The company believes Cannabidiols (CBD) Cannabinol ("CBN") could be a safer and better alternative for the treatment of sleep and anxiety disorders. 50 million Americans suffer from sleep and anxiety disorders, a large number of them use Prescription and/or OTC (over-the-counter) drugs, some of these drugs are habit forming, many Americans are unfortunately becoming drug-dependent and addicted to sleeping pills and pain killers and authorities are very concerned about the adverse social and economic consequences of the addiction problem.

For more information visit www.cbdlivin.com www.galaglobalinc.com

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] DailyStockDeals.com

 

Station Digital, SDIG, Profile, Summary

 

StationDigital Corporation

Multimedia Digital Broadcasting

 

StationDigital, SDIG, is a multimedia digital broadcast company that offers free music streaming of over 30 million songs. StationDigital features both genre-based and artist-based music discovery stations to suit an endless variety of musical tastes, and a personal recommendation service to its more than 2.4 million unique listeners – all available both online and through its iOS and Andriod mobile apps. StationDigital’s users can customize their listening experience by selecting playlists and stations based on themes, interests and location, as well as favorite artists, songs, genre, and by providing feedback on the music they hear.

 

StationDigital is the first truly next generation digital media broadcast platform.

StationDigital’s primary identity is as a sophisticated pure play music discovery Internet radio service, offering a competitive, state of the art product to capture market share in the Internet radio space. The Company has a unique, industry first value proposition - the StationDigital Listener Rewards Program, where all registered users earn listener rewards points:

 

> Every time users listen to StationDigital, either on the web or through their mobile apps

> Every time users share StationDigital with friends through social media

 

Key Features:

Social features and network effect – feedback on music, share music with friends and family, recommendations, post favorites on timeline, and earn reward points. Users can gain followers and build their own music social network of friends and fans.

Unique personalization of music to user’s taste – choose genre, artist, decade and ability to narrow search to a very specific target to get to songs faster. Features include ability to adjust music preferences, create a station playlist, and leverage songs from community of users.

Music discovery – with over 30 million songs and hundreds of stations providing a wide variety of categories and genres, users are always able to discover something new. Add/remove stations with one touch, smooth intuitive song catalog, 30 million songs, choose decade, genre, artist.

 

StationDigital will become the first agnostic, multimedia, global broadcast platform – available on any device, from anywhere, at anytime.

 

Investment Highlights

Opportunity to invest in an innovative, early stage next generation multimedia broadcast company with a unique and differentiated service and business model aimed at a rapidly growing and large market opportunity

The Company’s music streaming service has over 30 million songs for its 2.4 million users that offers customized listening, music discovery, a personal recommendation engine, a value-added social layer, and e-commerce platform

Key competitive differentiation factors are its unique listener rewards program/online store and wide variety of entertainment content options beyond music

Music streaming industry is still in its early stages and is experiencing rapid growth and market share capture from a large addressable $15 billion US radio market

Our valuation analysis results in a target price of $0.81 per share which represents significant upside of over 2 times the current stock price

 

see Investment Thesis click here

 

VALUATION

Starting with Pandora’s market cap per user of $38.63 and then applying a 65% discount to account for Pandora’s first mover advantage, dominant competitive position, and execution track record, we arrived at a market cap per user of $13.52. Based on management’s aggressive marketing plan, it can be estimated that StationDigital will have approximately 5 million monthly active users by the end of 2016. Applying this $13.52 market cap per user to 5 million monthly active user results in a StationDigital target market capitalization of $67.6 million or price per share of $0.81. Our target price of $0.81 is over 2.0 times the current share price of $0.40 providing significant upside price potential while also being only 35% above the Company’s recent high of $0.60 last October.

 

learn more about this great opportunity,

download the full research report now! click here

visit the company website www.StationDigitial.com

Start Enjoying the Music You Love!

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more,

please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

 

Herborium, HBRM, Profile, Summary

 

  

Herborium, HBRM, Profile, Summary

 

Herborium Group (HBRM) is a botanical therapeutics® company, develops, licenses and markets proprietary botanical based medicinal products to consumers and healthcare professionals.

Herborium develops its own formulations based on a herbaceutical science and other natural health resources including the traditional Chinese and herbal medicines from Peruvian Indians. These traditional botanical therapeutics are manufactured in technically advanced facilities strictly adhering to the FDA guidelines. The company's products are sold in The United States and Europe and, the company is planning to expand globally.

 

 

 

AcnEase®

Enhancing Beauty Botanically

 

The Company’s flagship product is AcnEase®, (www.acnease.com) a proprietary, all botanical acne treatment which has also been shown to improve conditions associated with Rosacea. The safety and efficacy of AcnEase has been validated by clinical testing. The results from these clinical studies demonstrated 96% improvement in both men and women with acne.

Over 60 million people in US and another 70-80 million in the Europe and Canada are estimated to suffer from acne (75% of individuals will have acne sometime in their life). The average age of individuals affected by acne increased during a last decade from 20 to 26 years old making adult acne one of a more prevailing health concerns.

The existing alternatives in the market for acne are limited to topical agents which treat existing acne, systemic antibiotics, and retinoic acid based products associated with severe side effects. A distinguishing characteristic of AcnEase aside from its remarkable safety profile is the products ability to prevent acne pimples from forming.

 

Lasting Pleasure for Women

More Power for Men!

A Natural Alternative for Female Sexual Dysfunction

 

Herborium’s Botanical Therapeutics® for Women (Lasting Pleasure) and Men (Lasting Power meet a growing interest in natural, safe sexual health products. Lasting Pleasure addresses the high demand for a “Viagra-like” product for women.

For female sexual dissatisfaction/dysfunction there currently are no systemic products available. The sole alternatives are topical agents and lubricants which have no impact on libido or female physical function.

The market for pharmaceutical grade sexual health products is over $3.2 billion worldwide with Viagra (Pfizer), Cialis (Eli Lilly) and Levitra (Bayer) leading market share. The market for natural sexual health products is estimated to be over $1.5 billion and growing. The rising costs of pharmaceutical grade sexual health drugs together with some safety concerns will drive consumers to look for alternatives in the market for natural sexual health products.

 

Key Strengths

 

>  Proof of Concept through Revenues Generation. Significant and consistent sales and profit growth

>  Proven ability to reduce time and therefore cost to market

>  Proven management team with considerable experience working with early stage companies, digital and social marketing, healthcare products, drug development, clinical studies, regulatory compliance and international business.

>  Regulatory know-how in the US and EU

>  Access to a rich pipeline of qualified medicinal compounds and herbal medicines

>  High level know-how in clinical research and pharmacological science

>  Access to quality and novel formulation know-how, FDA, GMP, ICH and EMEA compliant manufacturing capabilities and competencies.

>  Mitigation of investor risk, market entry risk, and therapeutic candidate risk based on initial data and screening performed in US, EU and Asia

>  Strong Big Pharma connection in the USA and EU for co-licensing or licensing and co-marketing opportunities

>  High Entry Barrier for competitors defined by the complex matrix of (Herborium’s) expertise indispensable to successfully managing the growing complexity of regulatory compliance, product development and market opportunities.

>  Consumer and healthcare providers recent trends towards natural, organic, safer, plant-based medicine

>  Healthcare economics stimulates search for new less expensive treatment options and encourages big Pharma and Insurance companies to look for consumer products and novel cost effective treatment options including Botanical Therapeutics®

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OTCKING.com

ACNE,Adult Acne, Teen Acne, Botanical Acne medications, Natural Acne Medications, Lasting Pleasure,Lasting Love, Lasting erection, Lasting Power, Hard Erection, Dry Vagina, Wet Vagina, Libido, sex thoughts, Easy Arousal. HBRM.Herborium.

 

Aethlon Medical, AEMD, Profile, Summary

Aethlon Medical, AEMD, Profile, Summary


 

Aethlon Medical (AEMD) is developing innovative medical devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon’s ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C.

 

HER2 Protein and Breast Cancer

Breast cancer is the most common form of cancer in women, accounting for 20% of cancer deaths with approximately 180,000 women diagnosed annually in the United States (Merrill, R. M., and A. Sloan. 2011. Risk-adjusted female breast cancer incidence rates in the United States. Cancer Epidemiol.). Over-expression of the human epidermal growth factor receptor 2 (HER2; ErbB2) gene occurs in approximately 25% of breast cancers and has been linked to poor prognosis (Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182). HER2 is a receptor tyrosine kinase, member of the EGF receptor family, which possesses proliferative and anti-apoptotic activities.

 

The standard of treatment for women diagnosed with HER2+ breast cancer includes the humanized monoclonal antibody trastuzumab (marketed as Herceptin®) directed against the extracellular domain of HER2. Trastuzumab binding to HER2 mediates direct growthinhibition of tumor cells and induces antibody-dependent cell cytotoxicity (ADCC), a major anti-cancer mechanism by which natural killer (NK) cells lyse antibody-coated tumor cells (Nahta, R., D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva. 2006. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280).

 

In patients with metastatic breast cancer undergoing chemotherapy, treatment with trastuzumab augments overall response rates and increases median survival time by 25% (Baselga, J. 2001. Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 37 Suppl 1:18-24). However, response rates to trastuzumab range from 12% to 34% with median duration of 9 months due to development of resistance. Despite co-treatment with other HER2 targeting therapies (e.g. the tyrosine kinase inhibitor lapatinib) and chemotherapy, patients with metastatic breast cancer experience a limited duration of benefit; therefore, novel treatment strategies that act synergistically or overcome drug resistance are urgently needed (Sachdev, J. C., and M. Jahanzeb. 2011. Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer.

 

The Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes

 

Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to improve treatment outcomes when administered at the outset of standard of care (SOC) drug therapy. This summary overview, which includes an introduction to the Aethlon Hemopurifier®, is for informational purposes only.

 

About HCV Infection

The U.S. National Institutes of Health (NIH) reports an estimated 180 million people worldwide are afflicted with chronic HCV infection. Of people infected, 55 to 85% of will develop chronic infection, and 75% of those will develop chronic liver disease. Standard of care (SOC) drug therapy is represented by a two drug combination of interferon and ribavirin. The primary goal of SOC drug therapy is the achievement of a sustained virologic response (SVR), defined as undetectable viral load six months after completion of SOC drug therapy. According to the NIH, 15-25% of HCV infected patients will recover

completely.

 

SOC Drug Therapy Outcomes

The largest study of HCV infected individuals pursuing 48-week SOC drug

therapy was a study of 4,469 genotype 1 patients published by McHutchison in The New England Journal of Medicine in August of 2009.

31% (1,399 of 4,469) of patients screened for participation were excluded from the study.

54% (1,654 of 3,070) of treated patients completed the SOC treatment regimen.

39.6% (1,215 of 3,070) of treated patients who completed SOC therapy

achieved a SVR.

27% (1,215 of 4,469) of the total patients screened for study participation

achieved a SVR.

No data recorded for patients who may have relapsed after achieving a SVR.

 

The Hemopurifier®

The first medical device to selectively remove HCV and related immunosuppressive proteins from circulation. A Study of the Hemopurifier® + SOC Drug Therapy is Now Underway

 

Patient enrollment has been initiated at the Medanta Medicity Institute in India - www.medanta.org

Additional details can be accessed from the Clinical Trials Registry - India (CTRI) link: http://ctri.nic.in/clinicaltrials/index.jsp

Up to 30 patients / up to 6 treatments in first 3 days of SOC

Early clinical endpoints include:

Immediate Virologic Response (IVR)

Rapid Virologic Response (RVR)

Early Virologic Response (EVR)

 

The Hemopurifier® Other Selected Quick Facts

 

70 human treatment experiences administered to date

An Investigation Device Exemption (IDE) to initiate U.S. studies has been filed with FDA

Substantial viral load reductions have also been observed in a human HIV study performed in the absence of antiviral drugs

GMP manufacturing has been established in an FDA approved facility

The Hemopurifier® has proven broad-spectrum capabilities against viral bioterror and pandemic threats

The device has been discovered to capture tumor-secreted exosomes known to suppress the immune system of cancer patients

 

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

ALS, Hepatitis C, Traumatic Brain Injury, Blood Sepsis,breast cancer,HIV,HPV,HCV,SOC, dialysis,DOD,UNT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD, Ebola

 

Premier Biomedical, BIEI, Profile, Summary

 

Premier Biomedical | BIEI | Profile | Summary


 

 

Premier Biomedical (BIEI) is a research-based company that has acquired exclusive licenses for patent-pending medications and medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses: ALS, Traumatic Brain Injury, Multiple Sclerosis, Clinical Depression, Alzheimer’s Disease, Blood Sepsis, and Cancer. The company is in the process of developing targeted medicines and procedures and will prove out their superior efficacy in addressing these diseases and others through laboratory, hospital, and actual patient applications. At the anticipated successful conclusion of the clinical trials, contact will be established with the leading worldwide pharmaceutical firms to establish the right to market and distribute Premier Biomedical’s technology products and procedures.
 

INVESTMENT HIGHLIGHTS

· The Company’s proprietary Sequential Dialysis Technique and patented candidate drug Feldetrex are expected to provide superior efficacy versus existing medications in treating a large number of the most fatal diseases

o Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique
 

EXECUTIVE SUMMARY

· Premier Biomedical is a research-based company that intends to discover and develop medical treatments targeting the treatment of:  Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects

o Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects

o Targets cancer, Alzheimer’s disease, Multiple Sclerosis, ALS, blood sepsis, and Traumatic Brain Injury – collectively over $700 billion market opportunity

 

· Developed a proprietary drug candidate Feldetrex as a potential treatment for Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury

o Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications

o The Company was recently granted two US patents for this drug candidate

oThe annual market size of all proposed market segments for Feldetrex is $16 billion

 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OTCking.com

Last Updated - Sunday, 02 November 2014
 
«StartPrev12345678910NextEnd»
Page 1 of 48
OTCStockWire
Sound View Plaza, 7th Floor
1266 E Main St.
Stamford, CT 06902, US
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become
a MEMBER Today!

Look for exclusive alerts

The Score Card

ARTI.PK* 0.0021   + 52%
EHSK.PK 0.17   + 108%
HGSI 3.35   + 226%
INCC.OB 0.01   + 346%
JGPK.OB 0.18   + 116%
STZU.PK 0.12   + 41%
TTEG.OB 0.36   + 156%

Most Active

 

Look us up ON
these and other
PREMIER FINANCIALweb sites.
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become a MEMBER Today!